UBS Group’s Organogenesis Holdings ORGO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $492K | Buy |
207,528
+74,920
| +56% | +$260K | ﹤0.01% | 6099 |
|
|
2025
Q4 | $687K | Sell |
132,608
-360,708
| -73% | -$1.75M | ﹤0.01% | 5877 |
|
|
2025
Q3 | $2.08M | Sell |
493,316
-6,055
| -1% | -$28.1K | ﹤0.01% | 4910 |
|
|
2025
Q2 | $1.83M | Buy |
499,371
+153,713
| +44% | +$573K | ﹤0.01% | 4915 |
|
|
2025
Q1 | $1.49M | Buy |
345,658
+288,762
| +508% | +$1.17M | ﹤0.01% | 4942 |
|
|
2024
Q4 | $182K | Sell |
56,896
-1,943
| -3% | -$6.52K | ﹤0.01% | 6507 |
|
|
2024
Q3 | $168K | Buy |
58,839
+11,797
| +25% | +$33.1K | ﹤0.01% | 6005 |
|
|
2024
Q2 | $132K | Sell |
47,042
-28,908
| -38% | -$77.6K | ﹤0.01% | 5972 |
|
|
2024
Q1 | $216K | Buy |
75,950
+1,613
| +2% | +$5.48K | ﹤0.01% | 5809 |
|
|
2023
Q4 | $304K | Buy |
74,337
+26,290
| +55% | +$73.6K | ﹤0.01% | 5485 |
|
|
2023
Q3 | $153K | Buy |
48,047
+46,046
| +2,301% | +$146K | ﹤0.01% | 5550 |
|
|
2023
Q2 | $6.64K | Sell |
2,001
-9,133
| -82% | -$27K | ﹤0.01% | 7349 |
|
|
2023
Q1 | $23.7K | Buy |
11,134
+5,137
| +86% | +$12.7K | ﹤0.01% | 6960 |
|
|
2022
Q4 | $16.1K | Buy |
5,997
+5,996
| +599,600% | +$17.5K | ﹤0.01% | 7920 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 10758 |
|
|
2022
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 10745 |
|
|
2022
Q1 | $0 | Sell |
1
-589
| -100% | -$4.56K | ﹤0.01% | 10712 |
|
|
2021
Q4 | $5K | Sell |
590
-179,118
| -100% | -$1.9M | ﹤0.01% | 9406 |
|
|
2021
Q3 | $2.56M | Buy |
179,708
+39,403
| +28% | +$612K | ﹤0.01% | 3368 |
|
|
2021
Q2 | $2.33M | Buy |
140,305
+137,988
| +5,955% | +$2.57M | ﹤0.01% | 3444 |
|
|
2021
Q1 | $42K | Sell |
2,317
-3,205
| -58% | -$43.4K | ﹤0.01% | 6728 |
|
|
2020
Q4 | $42K | Buy |
5,522
+4,378
| +383% | +$20.8K | ﹤0.01% | 6336 |
|
|
2020
Q3 | $4K | Sell |
1,144
-8,009
| -88% | -$31.6K | ﹤0.01% | 7424 |
|
|
2020
Q2 | $35K | Buy |
9,153
+2,408
| +36% | +$8.68K | ﹤0.01% | 6170 |
|
|
2020
Q1 | $22K | Sell |
6,745
-6,815
| -50% | -$29.2K | ﹤0.01% | 6440 |
|
|
2019
Q4 | $65K | Buy |
13,560
+3,148
| +30% | +$19.9K | ﹤0.01% | 6214 |
|
|
2019
Q3 | $68K | Buy |
10,412
+5,734
| +123% | +$31.9K | ﹤0.01% | 6005 |
|
|
2019
Q2 | $36K | Buy |
+4,678
| New | +$34.4K | ﹤0.01% | 6189 |
|
|
2018
Q3 | – | Sell |
-100
| Closed | -$1K | – | 8176 |
|
|
2018
Q2 | $1K | Hold |
100
| – | – | ﹤0.01% | 7828 |
|
|
2018
Q1 | $1K | Buy |
+100
| New | +$996 | ﹤0.01% | 7651 |
|
|
2017
Q4 | – | Sell |
-500
| Closed | -$5K | – | 8020 |
|
|
2017
Q3 | $5K | Hold |
500
| – | – | ﹤0.01% | 7224 |
|
|
2017
Q2 | $5K | Hold |
500
| – | – | ﹤0.01% | 7125 |
|
|
2017
Q1 | $5K | Buy |
+500
| New | +$4.94K | ﹤0.01% | 6987 |
|
Other funds holding ORGO
SCM
FLAM
VCM
UBS Group's ORGO Position: Q1 2026 in Review
UBS Group increased its Organogenesis Holdings (ORGO) stake by 56% in Q1 2026, buying an estimated $260K and bringing the position to 207,528 shares worth $492K. The position accounts for ﹤0.01% of the portfolio, ranked #6099.
UBS Group first reported a position in ORGO in Q1 2017 and has held it in 33 quarters since. The position peaked at $2.56M in Q3 2021. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.
- UBS Group held 207,528 shares of Organogenesis Holdings worth $492K as of Q1 2026.
- UBS Group bought 74,920 Organogenesis Holdings shares in Q1 2026, an estimated $260K.
- Organogenesis Holdings made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6099 holding.
- UBS Group first reported a position in Organogenesis Holdings in Q1 2017 and has held it in 33 quarters since.
- UBS Group's Organogenesis Holdings position peaked at $2.56M in Q3 2021.
- 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.